What the FDA labels say about taking them together
Buspirone and ziprasidone
Ziprasidone's FDA label of July 20, 2026 names buspirone in its drug interactions section; buspirone's label does not name ziprasidone itself but warns about its class (Atypical antipsychotics). The ziprasidone label: “The risk is increased with concomitant use of other serotonergic drugs and with drugs that impair metabolism of serotonin, i.e., monoamine oxidase inhibitors (MAOIs).”
Check it at the source: the buspirone FDA label on DailyMed (effective December 22, 2023, Unichem Pharmaceuticals (USA), Inc.); the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.).
What does the buspirone label say about ziprasidone?
Buspirone's label does not name ziprasidone itself; it warns about its class (Atypical antipsychotics):
Buspirone label, warningsSerotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs, SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs such as linezolid and intravenous methylene blue), or with antipsychotics or other dopamine antagonists.
Buspirone label, warningsTreatment with buspirone and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
Source: FDA drug label (Buspirone Hydrochloride), Unichem Pharmaceuticals (USA), Inc., effective December 22, 2023 (SPL set a6bdf140-075e-445e-a62d-633a4b97f3a8), via openFDA; the full label on DailyMed
What does the ziprasidone label say about buspirone?
Ziprasidone label, drug interactionsRisk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort [see Contraindications ( 4.3 ), Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6.2 )].
Ziprasidone label, warnings and precautionsThe risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., monoamine oxidase inhibitors (MAOIs) [see Contraindications ( 4.3 ), Adverse Reactions ( 6.2 ), Drug Interactions ( 7.3 )].
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buspirone | Ziprasidone | |
|---|---|---|
| Labeled for | Anxiety | Bipolar disorder, Schizophrenia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.043 per tablet 15 mg tablet | $0.269 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once